Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Open accessThe DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Abstract
Src is the prototypal member of Src Family tyrosine Kinases (SFKs), a large non-receptor kinase class that controls multiple signaling pathways in animal cells. SFKs activation is necessary for the mitogenic signal from many growth factors, but also for the acquisition of migratory and invasive phenotype. Indeed, oncogenic activation of SFKs has been demonstrated to play an important role in solid cancers; promoting tumor growth and formation of distant metastases. Several drugs targeting SFKs have been developed and tested in preclinical models and many of them have successfully reached clinical use in hematologic cancers. Although in solid tumors SFKs inhibitors have consistently confirmed their ability in blocking cancer cell progression in several experimental models; their utilization in clinical trials has unveiled unexpected complications against an effective utilization in patients. In this review, we summarize basic molecular mechanisms involving SFKs in cancer spreading and metastasization; and discuss preclinical and clinical data highlighting the main challenges for their future application as therapeutic targets in solid cancer progression
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to MAPK, SRC kinases can directly modulate many downstream targets including and c-MYC [19, 21, 22, 44], related to drug resistance and tumor cell survival.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SRC kinase, a cytoplasmic non-receptor tyrosine kinase, has been implicated in the development and progression of cancer [19–22].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
A pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“Drugs able to target Src were predicted in vitro to have a significant inhibitory effect on osteoclast activity [113].”
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
Rous, P. (1911) · Journal of Experimental Medicine · doi:10.1084/jem.13.4.397 · Cited by 1,051 · cited 1×
“Since the original identification of a transmissible agent responsible for the development of solid tumors in chickens, now known to be a retrovirus encoding the v-SRC, significant progress has been made in defining the functions of its human homolog, Src [44].”
Micalizzi, D. S., Farabaugh, S. M., & Ford, H. L. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9178-9 · Cited by 984 · cited 1×
“Similar results were obtained also in other tumors including prostate and renal cancer [62].”
Role of Src expression and activation in human cancer
Irby, R. B., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 857 · cited 1×
“The relationship between Src activation and cancer invasion, the most advanced phase of solid tumor progression, appears to be significant in a wide number of preclinical human cancer models, thus prompting the optimistic use of SFK inhibitors in clinical trials [45].”
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827 · cited 2×
“To date, most evidence suggests that Src has a predominant role in the maintenance of the invasive phenotype, rather than of the cell cycle progression [23].”
Structure and regulation of Src family kinases
Boggon, T. J., & Eck, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208081 · Cited by 712 · cited 1×
“The SH2 domain, consisting of about 100 amino acid residues, binds phosphorylated Tyr residues in C-terminal domain in the inactive conformation or, in the active form, on other proteins [30].”
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
Cited by
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer
Han, Q.-F., Li, W.-J., Hu, K.-S., Gao, J., Zhai, W.-L., Yang, J.-H., & Zhang, S.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01671-0 · Cited by 678
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Piccolo, S., Panciera, T., Contessotto, P., & Cordenonsi, M. (2022) · Nature Cancer · doi:10.1038/s43018-022-00473-z · Cited by 236
Ortiz, M. A., Mikhailova, T., Li, X., Porter, B. A., Bah, A., & Kotula, L. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00750-x · Cited by 154
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Pozniak, J., Bervoets, G., Van Raemdonck, N., Pedri, D., Swings, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.015 · Cited by 141
Metadata
- Authors
- Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A.
- Affiliations
- University of L'Aquila (IT)
- Biomedicine and Advanced Technologies Rieti Center “Sabina Universitas”, 02100 Rieti, Italy
- Università degli Studi della Tuscia (IT)
- Corresponding author
- Angelucci, Adriano
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-06-02
- Volume
- 12
- Issue
- 6
- Pages
- 1448
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7352436
- OpenAlex
- W3034094834
- Cited by
- 139
- References
- 176
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 21 · 2023: 31 · 2022: 17 · 2021: 26 · 2020: 4
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion, public-domain)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UnitusOpen (Tuscia University) (submittedVersion, public-domain)
- UnitusOpen (Tuscia University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca (2014-2020, DOT13SR6G7)
- Università degli Studi dell'Aquila
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- Src family kinases, tyrosine kinase inhibitors, solid tumors, metastasis, tumor progression, tumor cell migration and invasion, therapeutic target, drug resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far. https://app.cochat.ai/papers/10.3390/cancers12061448
- The paper
- Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A. (2020). Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far. Cancers. https://doi.org/10.3390/cancers12061448
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.